Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Astellas Pharma Inc

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

Benzinga

3 Top-Rated Pharma Stocks to Diversify Your Portfolio

The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY),…

StockNews.com

3 Affordable Pharma Stocks to Buy for Portfolio Gains

The pharmaceutical market is anticipated to grow substantially in the upcoming years, owing to technological innovation and rising demand for personalized medicines. To that end, affordable pharma stocks ACADIA Pharmaceuticals (ACAD), Astellas Pharma (ALPMY), and Spero Therapeutics (SPRO), trading under $20, could be solid buys now. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Gems Poised for Breakthroughs

The pharmaceutical industry is rapidly expanding, fueled by continued R&D efforts leading to the discovery of new drugs and therapies, biotechnology innovations, and growing medical needs. Thus, let’s take a look at pharma gems Pacira BioSciences (PCRX), Calliditas Therapeutics (CALT), and Astellas Pharma (ALPMY) poised for breakthroughs. Read more….

StockNews.com

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

3 Pharma Stocks to Buy Before Year-End

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Given the solid long-term prospects of the industry, fundamentally sound pharma stocks Spero Therapeutics (SPRO), Astellas Pharma (ALPMY) and Supernus Pharmaceuticals (SUPN) could be ideal buys for steady gains. Read on.

StockNews.com

3 Rising Pharma Stocks to Consider Buying Now

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Promising Pharma Stocks to Keep on Your Radar

The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma (ALPMY), Sanofi (SNY), and GSK (GSK) to one’s watchlist could be wise. Keep reading.

StockNews.com

3 Pharma Stocks to Buy for Value Investors

The pharma industry is well-positioned to witness significant growth due to the continuous advancements in artificial intelligence and increasing demand for innovative drugs. Therefore, fundamentally strong pharma stocks Merck & Co. (MRK), Astellas Pharma (ALPMY), and Taro Pharmaceutical (TARO), which seem to be trading at a discount, might be solid…

StockNews.com

3 Stocks With MAJOR Growth Potential

Considering the recent robust economic indicators and growing optimism, I think fundamentally strong growth stocks América Móvil (AMX), Astellas Pharma (ALPMY), and Bruker (BRKR) could be ideal investments. Continue reading.

StockNews.com

Secure Your Portfolio With These 3 Pharma Stocks

With rising global healthcare needs, investing in fundamentally sound pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Astellas Pharma (ALPMY) could help secure your portfolio by offering stability during economic uncertainties. Read on….

StockNews.com

3 Medical Stock Picks for Investors

As the demand for healthcare products and solutions continues to rise, the medical industry is poised for remarkable growth. Therefore, quality medical stocks Johnson & Johnson (JNJ), AstraZeneca (AZN), and Astellas Pharma (ALPMY) could be the ideal investments for your portfolio amid current market uncertainties. Read on….

StockNews.com

3 Value Stocks Investors Want

Strong recent economic data and still-elevated inflation are expected to keep the Fed on track for another interest rate hike next month. With the stock market likely to remain volatile amid rising interest rates and other macro uncertainties, fundamentally sound stocks Astellas (ALPMY), Alkermes (ALKS), and AstroNova (ALOT), trading at…

StockNews.com

Japan foreign minister Hayashi to visit Beijing on Saturday

Japan Foreign Minister Yoshimasa Hayashi said on Friday he will visit Beijing for two days from Saturday to discuss a range of issues, including the detention of an Astellas Pharma Inc employee.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Japanese man detained in China is Astellas Pharma employee - Kyodo

A Japanese man detained in China this month is a senior official of Astellas Pharma Inc, Kyodo news agency reported on Sunday citing a company spokesperson.

Benzinga

Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.

Benzinga

Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene Therapies.

Benzinga

Sutro Biopharma Stock Surges On Cancer Treatment Pact

Astellas Pharma Inc (OTC: ALPMF) and Sutro Biopharma Inc (NASDAQ:STRO) announced a strategic collaboration and licensing agreement focused on the discovery and development of immunostimulatory antibody-drug conjugates (iADC). iADCs are a next-generation modality for treating cancer and are designed to boost anti-cancer activity. They offer potential new options for patients who do not respond to existing…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold

The FDA has placed a clinical hold on Astellas Pharma Inc's (OTC:ALPMY) FORTIS Phase 1/2 trial following a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS trial is evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease. The FDA has…

Benzinga

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. Ligands in this pathway are…

StockNews.com

5 Top-Notch OTC Stocks to Buy This Month

Over-the-counter (OTC) stocks are generally deemed risky bets, but not all OTC stocks are bad investments. Moreover, given the surge in retail trading, we think OTC stocks Anglo American plc (NGLOY), ITOCHU (ITOCY), Astellas Pharma (ALPMY), A.P. Møller (AMKBY), and MTN Group (MTNOY) might soar in price in the near…

Benzinga

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial

After acing a pair of phase 3 trials, Astellas Pharma Inc (OTC:ALPMF) has reported the failure of fezolinetant to beat placebo in a late-stage study of patients in Asia. The study randomized 302 women in China, Korea, and Taiwan. After 12 weeks, Astellas saw numerical improvements in the rate of hot flashes from baseline…

Benzinga

Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing

Astellas Pharma Inc (OTC:ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor symptoms associated with menopause (VMS). The data will support future regulatory filing submissions. The study has met its primary objectives, including safety and tolerability and improvements in endometrial health at week…

Benzinga

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF)

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.